Status:
UNKNOWN
The Impact of Body Weight on Reproductive Outcomes in Poor Ovarian Responders in ICSI Cycles
Lead Sponsor:
Cairo University
Conditions:
Invitro Fertilization
Eligibility:
FEMALE
20-44 years
Phase:
NA
Brief Summary
Induction of ovulation cycle: 1. Gonadotrophines is started on day 2 with HMG(merional, IBSA) ,until the day of HCG administration(choriomon,IBSA10000IU) with starting dose 300 to 450iu. 2. GNRH anta...
Detailed Description
Induction of ovulation cycle: 1. Gonadotrophines is started on day 2 with HMG(merional, IBSA) ,until the day of HCG administration(choriomon,IBSA10000IU) with starting dose 300 to 450iu. 2. GNRH anta...
Eligibility Criteria
Inclusion
- 4- Poor responder according to ESHRE consensus; in which at least 2 of the following should be present: Advanced maternal age (≥ 40 years old) or any other risk factor A previous poor ovarian response (cycles cancelled or ≤ 3 oocytes with a conventional protocol)An abnormal ovarian reserve test (ORT); antral follicle count (AFC) \< 5-7 follicles or anti-mullerian hormone (AMH) ≤0.5- 1.1 ng/ml In the absence of advanced maternal age or abnormal ORT, two previous episodes of poor ovarian response after maximal stimulation patients are also considered poor responders according to ESHRE consensus.
- Presence and Adequate visualization of both ovaries Uterine cavity within normal anatomy assessed with HSG, hysteroscopy and TVUS
Exclusion
- Any factor which may affect reproductive outcome other than that the patient is a poor responder will be excluded from the study, like:
- Severe male factor .
- Uterine factor (eg: fibroid, polyp, Ashermann, .. etc)
- Immunological disorder (eg: SLE, APS, … etc)
- Thyroid or adrenal dysfunction
- Neoplasia (especially: hypothalamic, pit, ovarian)
- Women diagnosed with PCOS according to Rotterdam criteria
- Hydrosalpinx that hasn't been surgically removed or ligated.
- Untreated hyperprolactinemia
- Abnormal bleeding disorder
- Hepatic or renal dysfunction
- Hypersenstivity to study medication ( GNRH antagonist)
- Need to take medication that can influence ovarian stimulation
- Endometriosis grade 3 or 4
- Ovarian cyst\> 10 cm.
Key Trial Info
Start Date :
January 3 2015
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2018
Estimated Enrollment :
185 Patients enrolled
Trial Details
Trial ID
NCT03457233
Start Date
January 3 2015
End Date
March 1 2018
Last Update
March 7 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kasr Alainy medical school
Cairo, Egypt, 12111